Inhibition of hepatocellular carcinoma growth by antisense oligonucleotides to type I insulin-like growth factor receptor in vitro and in an orthotopic model

Hepatology Research

Volumn 37, Issue 5, 2007, Pages 366-375

  Lin, Ru Xian ^a   Wang, Zhi Yan ^a   Zhang, Nin ^b   Tuo, Chao Wei ^b   Liang, Qian De ^a   Sun, Yu Ning ^a   Wang, Sheng Qi ^a  

^a BEIJING INSTITUTE OF RADIATION MEDICINE   (China)

^b No 202 Hospital of PLA   (China)

Author keywords

Antisense oligonucleotide; Hepatocellular carcinoma; IGF IR

Indexed keywords

3 (4,5 DIMETHYL 2 THIAZOLYL) 2,5 DIPHENYLTETRAZOLIUM BROMIDE; ALPHA FETOPROTEIN; ANTINEOPLASTIC AGENT; ANTISENSE OLIGONUCLEOTIDE; ANTISENSE OLIGONUCLEOTIDE PHOSPHOROTHIOATE; FLUOROURACIL; LIPOFECTIN; MESSENGER RNA; OLIGONUCLEOTIDE PHOSPHOROTHIOATE; SOMATOMEDIN C RECEPTOR; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTISENSE THERAPY; ARTICLE; CANCER INHIBITION; CANCER RECURRENCE; CELL STRAIN HEPG2; CONTROLLED STUDY; CORRELATION ANALYSIS; DOSE RESPONSE; DOWN REGULATION; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG TARGETING; FEMALE; GENE EXPRESSION REGULATION; GENE OVEREXPRESSION; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LIVER CELL CARCINOMA; LUNG METASTASIS; MOUSE; NONHUMAN; ORTHOTOPIC TRANSPLANTATION; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TREATMENT RESPONSE; TUMOR VOLUME; TUMOR XENOGRAFT; WESTERN BLOTTING;

EID: 34247193659     PISSN: 13866346     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1872-034X.2007.00055.x     Document Type: Article

References (45)

1. Baserga R. The IGF-1 receptor in cancer research. Exp Cell Res 1999; 253: 1-6.
2. Scharf JG, Dombrowski F, Ramadori G. The IGF axis and hepatocarcinogenesis. Mol Pathol 2001; 54: 138-44.
3. Camirand A, Pollak M. Co-targeting IGF-IR and c-kit: Synergistic inhibition of proliferation and induction of apoptosis in H 209 small cell lung cancer cells. Br J Cancer 2004; 90: 1825-9.
4. Cullen KJ, Yee D, Sly WS et al. Insulin-like growth factor receptor expression and function in human breast cancer. Cancer Res 1990; 50: 58-63.
5. Kucab JE, Dunn SE. Role of IGF-IR in mediating breast cancer invasion and metastasis. Breast Dis 2003; 17: 41-7.
6. Hellawell GO, Turner GO, Davies DR, Poulsom R, Brewster SF, Macaulay VM. Expression of the type I insulin-like growth factor receptor is up-regulated in primary prostate cancer and commonly persists in metastatic disease. Cancer Res 2000; 62: 2942-50.
7. Kurek R, Tunn UW, Aumueller G, Renneberg H. Insulin-like growth factor-1 (IGF-1) and insulin-like factor receptor (IGFr-1) in prostate cancer. J Urol 2000; 163 (Suppl): 35.
8. Alexia G, Fallot G, Lasfer M et al. An evaluation of the role of insulin-like growth factors (IGF) and of type-I IGF receptor signalling in hepatocarcinogenesis and in the resistance of hepatocarcinoma cells against drug-induced apoptosis. Biochem Pharmacol 2004; 68: 1003-15.
9. Hassan AB, Macaulay VM. The insulin-like growth factor system as a therapeutic target in colorectal cancer. Ann Oncol 2002; 13: 349-56.
10. Kelly RG, Nally K, Shanahan F, O'Connell J. Type I insulin-like growth factor receptor expression on colorectal adenocarcinoma cell lines is decreased in response to the chemopreventive agent N-acetyl-1-cysteine. Ann N Y Acad Sci 2002; 973: 555-8.
11. Heron-Milhavet L, Karas M, Goldsmith CM, Baum BJ, Leroith D. Insulin-like growth factor-I (IGF-I) receptor activation rescues UV-damaged cells through a p38 signaling pathway. Potential role of the IGF-I receptor in DNA repair. J Biol Chem 2002; 276: 18185-92.
12. Kulik G, Klippel A, Weber MJ. Antiapoptotic signalling by the insulin-like growth factor I receptor, phosphatidylinositol 3-kinase, and Akt. Mol Cell Biol 1997; 17: 1595-606.
13. Nowak AK, Chow PK, Findlay M. Systemic therapy for advanced hepatocellular carcinoma: A review. Eur J Cancer 2004; 40: 1474-84.
14. Scharf JG, Braulke T. The role of the IGF axis in hepatocarcinogenesis. Horm Metab Res 2003; 35: 685-93.
15. Bahr C, Groner B. The insulin like growth factor-1 receptor (IGF-IR) as a drug target: Novel approaches to cancer therapy. Growth Horm IGF Res 2004; 14: 287-95.
16. Surmacz E. Growth factor receptors as therapeutic targets: Strategies to inhibit the insulin-like growth factor 1 receptor. Oncogene 2002; 22: 6589-97.
17. Salatino M, Schillaci R, Proietti CJ et al. Inhibition of in vivo breast cancer growth by antisense oligodeoxynucleotides to type I insulin-like growth factor receptor mRNA involves inactivation of ErbBs, PI-3K/Akt and p42/p44 MAPK signaling pathways but not modulation of progesterone receptor activity. Oncogene 2004; 23: 5161-74.
18. Yang JM, Chen WS, Liu ZP, Luo YH, Liu WW. Effects of insulin-like growth factors-IR and -IIR antisense gene transfection on the biological behaviors of SMMC-7721 human hepatoma cells. J Gastroenterol Hepatol 2003; 18: 296-301.
19. Sun HZ, Wu SH, Tu ZH. Blockage of IGF-IR signaling sensitizes urinary bladder cancer cells to mitomycin-mediated cytotoxicity. Cell Res 2001; 11: 107-15.
20. Rochester MA, Riedemann J, Hellawell GO, Brewster SF, Macaulay VM. Silencing of the IGF1R gene enhances sensitivity to DNA-damaging agents in both PTEN wild-type and mutant human prostate cancer. Cancer Gene Ther 2005; 12: 90-100.
21. Rose A, Froment P, Perrot V. The luteinizing hormone-releasing hormone inhibits the anti-apoptotic activity of insulin-like growth factor-1 in pituitary alphaT3 cells by protein kinase C alpha-mediated negative regulation of Akt. J Biol Chem 2004; 279: 52500-16.
22. Bohula EA, Playford MP, Macaulay VM. Targeting the type 1 insulin-like growth factor receptor as anti-cancer treatment. Anticancer Drugs 2003; 14: 669-82.
23. Min Y, Adachi Y, Yamamota H et al. Genetic blockade of the insulin-like growth factor-I receptor: A promising strategy for human pancreatic cancer. Cancer Res 2003; 63: 6432-41.
24. Seely BL, Samimi G, Webster NJ. Retroviral expression of a kinase-defective IGF-I receptor suppresses growth and causes apoptosis of CHO and U87 cells in-vivo. BMC Cancer 2002; 31: 2-15.
25. Burtrum D, Zhu ZP, Lu Dan et al. A fully human monoclonal antibody to the insulin-like growth factor 1 receptor blocks ligand-dependent signaling and inhibits human tumor growth in vivo. Cancer Res 2003; 63: 8912-21.
26. Goetsch L, Gonzalez A, Leger O et al. A recombinant humanized anti-insulin-like growth factor receptor type I antibody (h7C10) enhances the antitumor activity of vinorelbine and anti-epidermal growth factor receptor therapy against human cancer xenografts. Int J Cancer 2005; 113: 316-28.
27. Grimberg A, Cohen P. Growth hormone and prostate cancer: Guilty by association? J Endocrinol Invest 1999; 22: 64-73.
28. Ma J, Pollack MN, Giovannucci E et al. Prospective study of colorectal cancer risk in men and plasma levels of insulin-like growth factor (IGF) -1 and IGF-binding protein-3. J Natl Cancer Inst 1999; 91: 620-5.
29. Yu H, Spitz MR, Mistry J, Gu J, Hong WK, Wu X. Plasma levels of insulin-like growth factor-I and lung cancer risk: A case-control analysis. J Natl Cancer Inst 1999; 91: 151-6.
30. Hankinson SE, Willette WC, Colditz GA et al. Circulating concentration of insulin-like growth factor-1 and risk of breast cancer. Lancet 1998; 351: 1373-5.
31. Hellawell GO, Ferguson DJ, Brewster SF, Macaulay VM. Chemosensitization of human prostate cancer using antisense agents targeting the type 1 insulin-like growth factor receptor. BJU Int 2003; 91: 271-7.
32. Macaulay VM, Salisbury AJ, Bohula EA, Playford MP, Smorodinsky NI, Shiloh Y. Downregulation of the type 1 insulin-like growth factor receptor in mouse melanoma cells is associated with enhanced radiosensitivity and impaired activation of Atm kinase. Oncogene 2001; 20: 4029-40.
33. Caro JP, Poulos J, Ittoop O, Flickinger EG, Sinha MK. Insulin-like growth factor 1 binding in hepatocytes from human liver, human hepatoma, and normal, regenerating, and fetal rat liver. J Clin Invest 1998; 81: 976-81.
34. Charf JG, Schmidt-Sandte W, Pahernik SA, Ramadori G, Braulke T, Hartmann H. Characterization of the insulin-like growth factor axis in a human hepatoma cell line (PLC). Carcinogenesis 1998; 19: 2121-8.
35. Steinbach JP, Eisenmann C, Klumpp A, Weller M. Co-inhibition of epidermal growth factor receptor and type 1 insulin-like growth factor receptor synergistically sensitizes human malignant glioma cells to CD95L-induced apoptosis. Biochem Biophys Res Commun 2004; 321: 524-30.
36. Tsai TF, Yauk YK, Chou CK, Ting LP, Chang C, Hu CP. Evidence of autocrine regulation in human hepatoma cell lines. Biochem Biophys Res Commun 1988; 153: 39-45.
37. Armengol C, Tarafa G, Bolx L et al. Orthotopic implantation of human hepatocellular carcinoma in mice: Analysis of tumor progression and establishment of the BCLC-9 cell line. Clin Cancer Res 2004; 10: 2150-7.
38. Tarafa G, Villanueva A, Farre L et al. DCC and SMAD4 alterations in human colorectal and pancreatic tumor dissemination. Oncogene 2000; 19: 546-55.
39. Dunn SE, Kari FW, French J et al. Dietary restriction reduces insulin-like growth factor I levels, which modulates apoptosis, cell proliferation, and tumor progression in p53-deficient mice. Cancer Res 1997; 7: 4667-72.
40. Verspohl EL, Maddux BA, Goldfine ID. Insulin and insulin-like growth factor 1 regulate the same biological functions in HEP-G2 cells via their own specific receptors. J Clin Endocrinol Metab 1988; 67: 169-74.
41. Burfeind P, Chernicky CL, Rininsland F, Ilan J. Antisense RNA to the type I insulin-like growth factor receptor suppresses tumor growth and prevents invasion by rat prostate cancer cells in vivo. Proc Natl Acad Sci USA 1996; 93: 7263-8.
42. Long L, Nip J, Brodt P. Paracrine growth stimulation by hepatocyte-derived insulin-like growth factor-1: A regulatory mechanism for carcinoma cells metastatic to the liver. Cancer Res 1994; 54: 3732-7.
43. Long L, Rubin R, Brodt P. Enhanced invasion and liver colonization by lung carcinoma cells overexpressing the type 1 insulin-like growth factor receptor. Exp Cell Res 1998; 238: 116-21.
44. Brodt P, Samani A, Navab R. Inhibition of the type I insulin-like growth factor receptor expression and signaling: Novel strategies for antimetastatic therapy. Biochem Pharmacol 2000; 60: 1101-7.
45. Ijichi M, Takayama T, Matsumura M, Shiratori Y, Omata M, Makuuchi M. Alpha-fetoprotein mRNA in the circulation as a predictor of postsurgical recurrence of hepatocellular carcinoma: A prospective study. Hepatology 2003; 35: 853-60.